NUVA - NuVasive, Inc.
| Previous Close | 65.00 |
| Open | 65.67 |
| Bid | 66.67 x 1300 |
| Ask | 66.74 x 800 |
| Day's Range | 65.47 - 67.16 |
| 52 Week Range | 43.51 - 72.41 |
| Volume | 545,741 |
| Avg. Volume | 422,887 |
| Market Cap | 3.473B |
| Beta (3Y Monthly) | 1.25 |
| PE Ratio (TTM) | 67.80 |
| EPS (TTM) | 0.98 |
| Earnings Date | Oct 28, 2019 - Nov 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 67.75 |
- Zacks
Integra Buys Rebound Therapeutics to Boost Neurosurgery Line
Integra (IART) believes, Rebound's MIS technological arm will widen its neurosurgical pipeline within Codman Specialty Surgical space.
- PR Newswire
NuVasive to Participate as Double Diamond Sponsor at Scoliosis Research Society Annual Meeting
SAN DIEGO, Sept. 11, 2019 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will participate as a double diamond sponsor at the Scoliosis Research Society (SRS) 54th Annual Meeting held September 18-21, 2019 in Montréal, Canada. "NuVasive is committed to building the leading complex deformity portfolio in spine and we are pleased to continue our support of the Scoliosis Research Society as a double diamond sponsor," said Matt Link, president of NuVasive.
- Zacks
GNC Holdings Rides on New Pacts Amid Weak Same Store Sales
GNC Holdings' (GNC) recent joint venture with vitamins and nutritional supplement manufacturer International Vitamin Corporation shows high prospects at present.
- Zacks
Medtronic's (MDT) MiniMed 670G Gains German Reimbursement
Medtronic's (MDT) MiniMed 670G is witnessing a solid uptake in the United States ever since its launch last year.
- Simply Wall St.
Did NuVasive's (NASDAQ:NUVA) Share Price Deserve to Gain 68%?
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...
- Zacks
Illumina Banks on New Product Suite Despite Margin Woes
The unveiling of Veriseq NIPT v2 and Illumina's (ILMN) alliance with AnchorDx in the second quarter further raise investor confidence in the stock.
- Zacks
Abbott (ABT) Launches Pivotal Trial TRILUMINATE in the US
Given the lack of an alternative therapy to replace tricuspid regurgitation surgery, Abbott (ABT) should be at an advantage in this space.
- Zacks
Edwards Lifesciences Hits a 52-Week High on Solid Prospects
Edwards Lifesciences (EW) gains from recent impressive developments.
- Zacks
Here's Why You Should Invest in Amedisys (AMED) Right Now
Amedisys (AMED) is currently enjoying investors' confidence, thanks to solid prospects.
- Zacks
NuVasive Sees Hammer Chart Pattern: Time to Buy?
NuVasive, Inc. (NUVA) has been struggling lately, but the selling pressure may be coming to an end soon.
- Zacks
Integra LifeSciences' Organic Growth Strong on New Products
Gaining traction from product unveilings and an improved sales force performance, Integra LifeSciences (IART) expects rapid organic growth in the second half of 2019.
- Zacks
Medtronic Names Next CEO as Omar Ishrak to Step Down in 2020
This is indeed a top story as during Omar's tenure, annual revenues of Medtronic (MDT) skyrocket to double-digit growth among a slew of enormous feats that he attains.
- Zacks
Bruker (BRKR) Releases JPK NanoWizard 4 XP Bio-AFM System
With the launch of this new system, Bruker (BRKR) establishes a performance yardstick for atomic force microscopy in the field of life science research.
- Zacks
Here's Why You Should Invest in Haemonetics (HAE) Right Now
Haemonetics (HAE) has been enjoying investors' rising optimism, owing to solid prospects.
- Zacks
Here's Why You Should Invest in Hologic (HOLX) Stock Now
Hologic (HOLX) is generating consistently positive results, thanks to impressive developments.
- Zacks
Zimmer Biomet Succeeds in Priority Areas, Suffers Pricing Woe
With regard to product suite, Zimmer Biomet (ZBH) steadily wins an array of key regulatory clearances for knee, brain and spine applications under its ROSA platform over the past several months.
- Zacks
Quest Diagnostics' New Acquisitions and Pacts Aid Growth
Quest Diagnostics' (DGX) nine deals concluded in 2018 strengthen its potential to fulfill its goals set for 2019.
- Zacks
Why Is NuVasive (NUVA) Down 4.2% Since Last Earnings Report?
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Thomson Reuters StreetEvents
Edited Transcript of NUVA earnings conference call or presentation 30-Jul-19 8:30pm GMT
Q2 2019 NuVasive Inc Earnings Call
- GlobeNewswire
Alphatec Announces Favorable Judgment in NuVasive v. Miles Lawsuit
Alphatec Holdings, Inc. (“ATEC” or “the Company”) (ATEC), a medical device company dedicated to revolutionizing the approach to spine surgery, announced today that the Delaware Chancery Court entered summary judgment in favor of its Chairman and Chief Executive Officer, Pat Miles, terminating all non-competition and employee non-solicitation claims brought against Miles and the Company by competitor, NuVasive, Inc. (NUVA).
- PR Newswire
NuVasive to Participate in Investor Events in September 2019
NuVasive, Inc. (NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company's portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings.
- Zacks
Medtronic (MDT) Benefits from Strength Across Business Groups
Within RTG, Medronic's (MDT) neurosurgery arm is gaining on strong uptake of Mazor X Stealth navigated robotic system.
- Zacks
Boston Scientific Closes BTG Buyout, PI Arm to Get a Boost
In its effort to accommodate the acquisition of BTG, Boston Scientific (BSX) is offloading its certain non-prior businesses.
- Zacks
NUVA vs. LZAGY: Which Stock Is the Better Value Option?
NUVA vs. LZAGY: Which Stock Is the Better Value Option?
- Zacks
Here's Why You Should Invest in NuVasive (NUVA) Stock Now
Investor confidence is currently high on NuVasive's (NUVA) prospects.
